12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

SNS01-T: Additional Phase Ib/IIa data

Interim data from 3 evaluable patients in the first cohort of an open-label, dose-escalation, U.S. Phase Ib/IIa trial showed that 0.0125 mg/kg SNS01-T led to 2 cases of stable disease, including 1 patient who remained stable at 4 weeks and progressed at 8 weeks...

Read the full 196 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >